Table: Otsuka Holdings -Q1 group results (IFRS)
Apr 28 (Reuters)-
Otsuka Holdings Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
3 months ended 3 months ended Year to
Mar 31, 2026 Mar 31, 2025 Dec 31, 2026
LATEST YEAR-AGO COMPANY
RESULTS RESULT FORECAST
Sales 630.34 582.84 2.52 trln
(+8.2 pct) (+12.2 pct) (+2.1 pct)
Operating 126.29 124.42 360.00
(+1.5 pct) (+35.2 pct) (-24.9 pct)
Pretax 130.23 113.37
(+14.9 pct) (+13.3 pct)
Net 98.35 85.00 265.00
(+15.7 pct) (+9.8 pct) (-27.0 pct)
EPS Basic 186.31 yen 158.57 yen 504.94 yen
Ann Div 140.00 yen 140.00 yen
-Q2 Div 70.00 yen 70.00 yen
-Q4 Div 70.00 yen 70.00 yen
NOTE - Otsuka Holdings Co Ltd.
(Figures are reported based on international accounting rules (IFRS).)
If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half
dividend and Q4 to the second-half dividend announced before a new corporate law in
2006 allowed companies to pay and report dividends on a quarterly basis.
*Net - represents Net profit attributable to owners of the parent company.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4578.T
Recent news on Otsuka Holdings
See all newsOtsuka, Ionis' experimental ALS drug meets main goal in late-stage study
Brief: Otsuka Pharmaceutical Announces Ulefnersen Early Access Program For Eligible People Living With FUS-ALS
Brief: Otsuka Pharmaceutical Says Phase 3 Fusion Results For Ulefnersen Met Primary Endpoint
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit In Rezilient3 Phase 3 Trial In First-Line Egfr Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Climb Bio rises after early-stage data for kidney disease drug